Bio-Matrix Scientific Group’s Regen BioPharma Subsidiary Announces HemaXellerate As First Product in Development

San Diego, CA (PRWEB) October 03, 2012

Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc. has begun development of HemaXellerate, its first clinical product. HemaXellerate is a cellular drug designed to heal damaged bone marrow. Typically, bone marrow is damaged by chemotherapy, radiation therapy, or diseases such as anemia.

As part of the development process, on May 18, 2012, Regen submitted a provisional patent application covering the use of placentally-derived endothelial cells for treatment of bone marrow failure. Regen has also been granted an exclusive option to enter into an agreement to be granted an exclusive, worldwide, royalty bearing license to US patent No. 6,821,513, covering a proprietary method for enhancing hematopoiesis (formation of blood cells).

Current approaches to treating bone marrow disorders involve administration of pharmaceuticals which target stem cells to produce more blood. This approach is not effective on everyone with bone marrow failure and some forms of this disease are completely resistant said J. Christopher Mizer, President of Regen BioPharma. Our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally.

Data from a peer reviewed publication (Lei et al. Stem Cell Res. 2010 January; 4(1): 1724) by the inventor of the patent demonstrated that the administration of endothelial cells restores blood production and extends survival after bone marrow damage.

The HemaXellerate product aims to address the unmet medical need of patients who are non-responsive to existing growth factor therapies such as Neupogen and Leukine. These patients include those suffering from: aplastic anemia, a condition where the bone marrow produces an insufficient number of new cells to replace lost blood cells; chemotherapy/radiotherapy induced bone marrow failures; and low blood cell production after bone marrow or cord blood transplants, stated Thomas Ichim, Chief Scientific Officer of Regen BioPharma.

According to David Koos, Chairman & CEO of Bio-Matrix, HemaXellerate may provide an ideal therapeutic for bone marrow failure based upon: (1) regulating secretion of cytokines as biologically needed; (2) producing long-term, localized growth factors that alleviate the need for drugs; and (3) actively repairing the blood producing stem cell environment.

A spokesperson for the Company said Regen intends to file an Investigational New Drug (IND) Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:

Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) is a biotechnology company developing regenerative medicine therapies and tools. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.

Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks

Contact Information


Bio-Matrix Scientific Group, Inc.

David R. Koos, PhD

Chairman & Chief Executive Officer



This entry was posted in Biotechnology and tagged , , , , , , , , , , . Bookmark the permalink.

Leave a Reply